Activity of tannins from *Stryphnodendron adstringens* on *Cryptococcus neoformans*: effects on growth, capsule size and pigmentation

Kelly Ishida¹, Sonia Rozental*¹, João Carlos Palazzo de Mello² and Celso Vataru Nakamura³

**Abstract**

**Background:** *Stryphnodendron adstringens* (Mart.) Coville, Leguminosae, also known in Brazil as barbatimão, is rich in tannins and many flavan-3-ols and proanthocyanidins such as prodelphinidins and prorobinetidins. Previous studies have demonstrated several pharmacological properties of tannins from barbatimão, including anti-candidal activity.

**Methods:** The antifungal activity of proanthocyanidin polymeric tannins from *Stryphnodendron adstringens* (subfraction F2.4) was evaluated against three strains of *Cryptococcus neoformans* with different capsule expressions, using the broth microdilution technique, light microscopy and transmission electron microscopy. The effect of subfraction F2.4 on *C. neoformans* and melanoma mammalian cells pigmentation was also evaluated.

**Results:** Although susceptibility assays revealed MIC values quite similar (between 2.5 and 5.0 μg/ml), analyses of MFC values revealing that the acapsular mutant Cap 67 was more susceptible to be killed by the subfraction F2.4 (MFC = 20 μg/ml) than the two tested capsular strains (T1-444 and ATCC 28957) (MFC > 160 μg/ml). Optical and electron microscopy experiments revealed relevant alterations in cell shape and size in all strains treated with 1 and 2.5 μg/ml of subfraction F2.4. Capsule size of the capsular strains decreased drastically after subfraction F2.4 treatment. In addition, ultrastructural alterations such as cell wall disruption, cytoplasm extraction, mitochondria swelling, increase in the number of cytoplasmic vacuoles and formation of membranous structures in the cytoplasm were also observed in treated yeasts. Incubation with subfraction F2.4 also decreased *C. neoformans* pigmentation, however, did not interfere in melanization of B16F10 mammalian cells.

**Conclusion:** Our data indicate that tannins extracted from *S. adstringens* interfered with growth, capsule size and pigmentation, all important virulence factors of *C. neoformans*, and may be considered as a putative candidate for the development of new antifungal agents.
Background

*Stryphnodendron adstringens* (Mart.) Coville, Leguminosae, also known in Brazil as barbatimão, is used in the form of a decoction or infusion as an adstringent, anti-diarrhoeal, antimicrobial and hypoglycaemic agent for the treatment of gynaecological problems and healing wounds [1]. The stem bark of barbatimão is rich in tannins (10-37%) [2], many flavan-3-ols and proanthocyanidins such as prodelphinidins and prorobinetinidins [3,4]. Previous studies have demonstrated cicatrizizing properties [5], analgesic and anti-inflammatory activity [6,7] and gastric anti-ulcerogenic effects [8] of the tannins extracted from the stem bark of barbatimão.

Also the anti-protozoal effect of tannins from barbatimão has been described against *Herpetomonas samuelepessoa* [9], *Trypanosoma cruzi* and *Leishmania amazonensis* [10,11] and antiviral activity against bovine herpesvirus and poliovirus were also demonstrated by Felipe et al. [12]. In addition, our group showed a high antifungal activity of a polymeric tannin (hexameric compound) extracted from the stem bark of barbatimão, against clinical isolates of *Candida albicans* [13].

*Cryptococcus neoformans* is an encapsulate opportunistic yeast that can cause cryptococcosis, predominantly in immunocompromised patients with underlying predisposing factors, such as organ transplantation, haematological malignancies and advanced human immunodeficiency virus diseases [14]. This yeast is ubiquitous in the environment and is acquired by inhalation of desiccated particles, causing pulmonary cryptococcosis that may be accompanied by systemic dissemination and it usually manifests itself as meningoencephalitis [14]. The choice of treatment for cryptococcosis depends on the anatomic sites of involvement and the host's immune status. Treatment is usually based on amphotericin B therapy with or without fluotycosine and azole agents. Fluconazole and itraconazole are the drugs of choice for prophylaxis and maintenance therapy [15]. Although resistance to antifungal drugs is rare in *C. neoformans*, long-term suppressive regimens are raising concern about the development of drug resistance [16]. In addition to the limited number of available therapeutic options to treat cryptococcal infections, prolonged therapy may increase the toxic effects of these drugs on the patient.

*C. neoformans* is unique among pathogenic fungi in having a polysaccharide capsule, mainly composed of glucuronoxylomannan (GXM) and galactoxylomannan (GalXM), which is considered the major contributor to its virulence. GXM and GalXM units can be released during cryptococcal infection with deleterious effects to the host immune function, such as anti-phagocytic and immunosuppressive capacity [17].

Melanin synthesis during infection is also considered an important factor in the virulence of *Cryptococcus*. Melanin protects from oxygen and nitrogen oxidants, microbial peptide activity, ingestion and killing by macrophages. In addition, melanized *C. neoformans* are less susceptible to antifungal agents [18].

Drugs interfering in the growth and virulence factors of *C. neoformans* can be considered stronger candidates for the study and development of new antifungal agents. The aim of this study was to evaluate the antifungal activity of the polymeric tannin (hexameric compound) extracted from stem bark of *S. adstringens* against *C. neoformans* strains and to observe its effect on cell growth, morphology, ultrastructure, capsule size and pigmentation.

Methods

**Extraction and characterization of subfraction F2.4 from *S. adstringens***

The stem bark of *S. adstringens* was collected, dried and powdered. The crude extract, fractions and subfractions (including F2.4) were obtained as described by Ishida et al. [13]. Briefly, the crude extract was obtained by turo-extraction (Skymsen) of 100 g of the bark with 70% acetone in water for 20 min. The organic solvent was eliminated by reduced pressure and lyophilized to yield a crude extract (F1). Next, the F1 (36 g) was suspended in water (360 mL) and partitioned with ethyl acetate (360 mL) to obtain a water fraction (F2) and an ethyl acetate fraction (F3). The F2 fraction (2 g) was chromatographed on a Sephadex LH-20 column (h = 170 mm; r = 21 mm, Pharmacia), using one sequence of eluent system of volumetric proportions with water (50% ethanol, 70% ethanol, 90% ethanol and 70% acetone), obtaining four subfractions. Chemical characterization of subfraction F2.4 was analysed by mass spectrometry ES-MS and $^{13}$C NMR spectroscopy and characterized as a proanthocyanidin polymer (a hexameric compound), composed of prodelphinidin and prorobinetinidin units and gallic-acid residues, with an average molecular weight of 2,114 Da. For the experiments realized in this work, the subfraction F2.4 lyophilized powder (maintained at -20°C freezer) was diluted directly in RPMI 1640 medium.

**Microorganisms**

Strains of *C. neoformans* with different capsular expressions were used in this study. *C. neoformans* T1-444 (serotype A, capsular size around 2.85 μm) is a clinical isolate from a patient with meningoencephalitis and AIDS, provided by the Hospital of São Paulo Federal University. The other two strains (ATCC 28957 - isolated from human bone lesion - capsular size around 2.66 μm) and Cap 67 acapsular mutant [19] were purchased from the American Type Culture Collection (ATCC). Cap 67 acapsular mutant is deposited in the American Type Culture Collection as ATCC 52817. Stock cultures were maintained on...
Sabouraud dextrose agar, at 4°C. Subcultures were made for each experiment in the same medium, at 35°C, for 72 h.

**Culture cells**

B16F10 murine melanoma cells were kindly provided by Dr. J. Morgado-Díaz (Instituto Nacional de Cancer, Divisão de Biologia Celular, Rio de Janeiro/Brazil) and maintained in RPMI 1640 medium (Gibco Invitrogen Corporation, New York, USA), supplemented with 2 mM L-glutamine and heat-inactivated 10% foetal bovine serum, buffered with sodium bicarbonate and 50 μg/ml gentamicin. The cultures were maintained at 37°C, in 5% CO2.

**Anti-cryptococcal activity of subfraction F2.4**

Minimum inhibitory concentration (MIC) determination was performed as described in document M27-A3 [20]. Briefly, a two-fold serial dilution of subfraction F2.4 in RPMI 1640 medium without sodium bicarbonate (Sigma Chemical Co., MO, USA) buffered with 0.165 M MOPS (Sigma Chemical Co., MO, USA) was made in 96-well microtitre trays, to obtain concentrations of 0.31 to 160 μg/ml. A suspension of C. neoformans of 1-5 × 10⁶ cfu/ml was prepared, diluted 1:1000 and 100 μl was dispensed into each well containing 100 μl of medium to obtain a final concentration of 0.5-2.5 × 10³ cfu/ml. The microtitre trays were incubated at 35°C for 72 h in a humid chamber. The MIC values were considered to be the lowest concentration that visibly inhibited cryptococcal growth. Fluconazole (Pfizer, São Paulo, Brazil), itraconazole (Sigma Chemical Co., MO, USA), and amphotericin B (Sigma Chemical Co., MO, USA) were used as standard antifungal.

Minimum fungicidal concentration (MFC) was determined using an aliquot of 10 μl of the yeast suspension treated with inhibitory concentrations of subfraction F2.4 and subcultured on a drug-free Sabouraud dextrose agar, incubated at 35°C, for 72 h. The MFC was determined as the lowest concentration that showed negative culture [13].

**Light microscopy**

Strains of C. neoformans were treated with 1 and 2.5 μg/ml of subfraction F2.4 in RPMI 1640 medium buffered with 0.165 M MOPS, for 72 h, at 35°C. The yeasts were collected, washed in PBS, pH 7.2 and negatively stained with India ink. The images were observed by differential interference contrast (DIC) microscopy with an Axiosplan 2 (Zeiss, Germany) optical microscope, acquired using a Color View SX digital camera and processed with the program analysis (Soft Image System, Germany). Morphological alterations and budding cells were counted in at least 300 yeasts. The cell and capsule size were measured by the SemAfore 5.0 program (Jeol, Japan).

**Transmission electron microscopy**

Strains of C. neoformans were treated with 1 and 2.5 μg/ml of subfraction F2.4 for 72 h, at 35°C. The yeasts were collected, washed in PBS, pH 7.2 and then fixed in 2.5% glutaraldehyde and 4% paraformaldehyde, in 0.1 M cacodylate buffer. They were then post-fixed in 1% osmium tetroxide in cacodylate buffer containing 1.25% potassium ferrocyanide and 5 mM CaCl₂ for 2 h, serially dehydrated in ethanol and embedded in Spurr epoxy resin. Ultrathin sections were obtained on a Reichert Ultracut, stained with 5% uranyl acetate and 0.5% lead citrate and observed in a Zeiss CEM-900 electron microscope.

**Effect of subfraction F2.4 on cryptococcal pigmentation**

Minimum agar medium (15 mM dextrose, 10 mM MgSO₄, 29.4 mM KH₂PO₄, 13 mM glycine, 3 μM thiamine-HCl and 2% agar) supplemented with 1 mM L-3,4-dihydroxyphenylalanine (L-dopa, Sigma Chemical Co., MO, USA) was used to induce melanization of C. neoformans. Subfraction F2.4 was diluted in minimum agar medium to obtain concentrations of 5 to 100 μg/ml. An aliquot of 20 μl of 1 × 10⁶ cfu/ml of the C. neoformans suspension was dispensed on the medium and then incubated in a dark humid chamber for 5 days, at 35°C. Medium without L-dopa was used as a negative control for melanin synthesis. Medium - without yeast - supplemented with L-dopa was used to observe if autopolymerization occurred.

The images were obtained using a transilluminator and a digital camera without flash illumination. The colony pigmentation was measured using the program Image J, developed by the National Institutes of Health (NIH, USA) http://rsb.info.nih.gov/ij/. The percentage of pigmentation inhibition was calculated by comparison with the positive control for cryptococcal pigmentation.

**Effect of subfraction F2.4 on B16F10 cell melanogenesis**

A B16F10 cell suspension of 2.5 × 10⁵ cell/ml was dispersed into each well of 6-well microplates, for 24 h, to allow the cells to adhere. Subsequently, the cells were treated with several concentrations of subfraction F2.4 (1, 10, 50, and 100 μg/ml) for 48 h, at 37°C and 5% CO₂. The cell monolayers were resuspended in PBS, pH 7.2, and counted in a haemocytometer chamber. Cell suspension was treated with 1 N NaOH for 24 h, at 37°C, for melanin extraction. Absorbance was determined in a spectrophotometer (Model UV-1700-Pharmaspec, Shimadzu, Japan) at 475 nm wavelength. Melanin concentration was determined using a standard curve for synthetic melanin (Sigma Chemical Co., MO, USA). Synthetic melanin standard curve was constructed using 0.78, 1.56, 3.12, 6.25, 12.5, 25 and 50 μg/ml of melanin diluted in 1 N NaOH and the absorbance at 475 nm wavelength of each concentration was obtained with a quartz cuvette containing 1 ml of
each solution. Background of the each concentration was subtracted using absorbance the 1 N NaOH solution. The melanin standard curve presented a linear profile ($R^2 = 0.9999$). Than, melanin concentration per $10^5$ cells was calculated.

Statistical analysis
The results were analyzed using the Prism 5.0 computer program. The data obtained in experimental models were evaluated by one-way analysis of variance (ANOVA) followed by Dunnett's test. Differences between the control group and the drug groups raw means were considered to be statistically significant when $p < 0.05$.

Results
Anti-cryptococcal activity of polymeric tannin from S. adstringens
The MICs of subfraction F2.4 were 2.5 and 5 $\mu$g/ml to acapsular and capsular strains, respectively (Table 1). Additionally, sub-inhibitory concentrations, 1 and 2.5 $\mu$g/ml, of subfraction F2.4 inhibited the growth of ATCC 28957 strain by 16.67% and 36.67%, respectively and of Cap 67 strain by 56.87% and 86.87%; but did not inhibit the growth of T1-444 strain. Although the acapsular strain Cap 67 had shown similar susceptible to subfraction F2.4 as the T1-444 and ATCC 28957 strains, the MFC values of Cap 67 were at least 8 times lower when compared to the MFC values of the capsular strains (Table 1). T1-444, ATCC 28954 and Cap 67 strains were all susceptible to fluconazole, itraconazole and amphotericin B. We did not find any relevant differences between the MIC or MFC values of the three tested strains in relation to fluconazole, itraconazole and amphotericin B (Table 1).

Light microscopy
In order to examine the effect of subfraction F2.4 on the morphology of capsular (ATCC 28954 and T1-444) and acapsular (Cap 67) strains of C. neoformans, the yeasts were cultivated or not (control cells) in the presence of the drug and examined by light microscopy. Control capsular cells showed a regular oval cell shape and are homogeneously surrounded by the polysaccharide capsule (Figs. 1A and 1F). The treatment of the strains with 1 and 2.5 $\mu$g/ml of subfraction F2.4 lead to a significant reduction in capsule size (Figs. 1E and 1J) and decrease of cell size when compared with the control cells (Figs. 1E and 1J).

Treatment of these yeasts with subfraction F2.4 also leads to several morphological alterations such as: (i) the non separation of young bud cells (Figs. 1B-C and 1G-H); (ii) elongation of the young buds (Fig. 1H); and (iii) appearance of smaller and anamorphous yeasts (Figs. 1D and 1I). The capsular strains of C. neoformans did not show any significant differences in the counting of the yeast budding.

The untreated yeasts of C. neoformans Cap 67 showed agglomerate yeasts characteristic of this strain (Fig. 1K). For this reason, it was not possible to count the yeast buds. No significant alteration in cell size was observed. However, we observed many changes in yeast morphology such as the appearance of decreasing moon (Fig. 1M) and of globular cells (Fig. 1N) after incubation with subfraction F2.4.

Transmission electron microscopy
Untreated yeasts had a compact cell wall (cw), capsule (c) and a cytoplasm with a regular electron density and many ribosomes (Fig. 2A). Ultrastructural analyses of C. neoformans ATCC 28957 revealed several morphological alterations after treatment with subfraction F2.4 (Figs. 2B-F). Yeast of C. neoformans ATCC 28957 treated with 1 $\mu$g/ml of the subfraction F2.4 showed disruption of the cell wall (arrow, in Figs. 2C-D), changes in the yeast morphology and in the budding process (Figs. 2C-D). The presence of membranous structures (arrowheads, in Figs. 2B-C), large vacuoles (v, in Fig. 2D), mitochondria swelling (m, in Fig. 2B) were found in the cytoplasm of the treated yeasts. Yeasts treated with 2.5 $\mu$g/ml of subfraction F2.4 showed more-drastic alterations with irregular buds emerging from the lateral of the mother cells instead of from the usual terminal, complete loss of the normal cellular oval shape, cell wall detachment (arrows), membranous structures (arrowheads) and extracted cytoplasm suggest-

| Drugs          | C. neoformans T1-444 | C. neoformans ATCC 28957 | C. neoformans Cap67 |
|----------------|----------------------|--------------------------|---------------------|
|                | MIC | MFC   | MIC | MFC   | MIC | MFC   |
| Subfraction F2.4 | 5   | >160  | 5   | >160  | 2.5 | 20    |
| Fluconazole     | 4   | 16    | 2   | 8     | 2   | 8     |
| Itraconazole    | 0.12| 8     | 0.12| 8     | 0.03| 8     |
| Amphotericin B  | 0.12| 0.25  | 0.06| 0.25  | 0.06| 0.12  |

Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) are in $\mu$g/ml.
Figure 1
Morphological alterations of *C. neoformans* strains (T1-444, ATCC 28957 and Cap 67 strains) treated with 1 and 2.5 μg/ml of subfraction F2.4 from *S. adstringens*. **A, F and K**: Control; **B, G and L**: 1 μg/ml; **C-D, H-I and M-N**: 2.5 μg/ml; **E, J and O**: capsule and cell size (μm) of *C. neoformans* strains untreated and treated with subfraction F2.4. 

**p** < 0.01.
ing cell death (Figs. 2E-F). The T1-444 strain showed similar alterations in cellular ultrastructure, however less pronounced than the ATCC 28957 strain (data not shown).

Yeasts of the acapsular mutant (Cap 67) presented more drastic alterations when grown in the presence of 1 μg/ml (B-D) or 2.5 μg/ml (E-F) of subfraction F2.4. The ultrastructure of untreated yeasts was preserved, with compact cell wall (cw), nucleus (n), nucleolus (nu), mitochondria (m) and electron-dense glycogen granules (Fig. 3A). In contrast, treated yeasts showed many ultrastructural alterations such as budding of vesicular bodies into vacuoles lumen (Fig. 3C, white asterisk), cell wall disassembling (arrows in Figs. 3D-E), an increase in number and size of electron lucent vacuoles (v) (Figs. 3B-C and 3F) and intracellular membranous structures (arrowheads in Figs. 3E-F). These membranous structures were also observed inside the vacuoles (arrowheads in Fig. 3C).

**Polymeric tannin reduce cryptococcal pigmentation**

*C. neoformans* treated with subfraction F2.4 grown in minimum agar medium supplemented with 1 mM L-dopa were significantly less pigmented than the control cells (Fig. 4). The hexameric condensed tannin was more active to inhibit the pigmentation of the acapsular strain Cap 67 than the capsular strains. Pigmentation was strongly reduced in Cap 67 at concentrations of 10-100 μg/ml...
affect T1-444 strain pigmentation at concentrations ≤2.4 (35.1%, p < 0.01). The polymeric tannin did not affect the MIC values of the three strains the MFC results for the capsular strains, although only small differences were observed between the strains treated with several concentrations of the subfraction F2.4 (5 to 100 μg/ml). Subfraction F2.4 from S. barbatimão reduced the pigmentation of C. neoformans with different capsule expressions. ***p < 0.01; **** p < 0.001.

Figure 4
Pigmentation percentage of C. neoformans strains treated with several concentrations of the subfraction F.24 (5 to 100 μg/ml) in minimum medium supplemented with 1 mM L-dopa. Subfraction F2.4 from S. barbatimão reduced the pigmentation of C. neoformans with different capsule expressions. ***p < 0.01; **** p < 0.001.

Effect of the polymeric tannin on melanogenesis of B16F10 cells
The effect of subfraction F2.4 on mammalian cell (B16F10) melanogenesis was also evaluated. Concentrations ≤100 μg/ml of subfraction F2.4 did not alter melanin synthesis in B16F10 cells (p > 0.05) (data not shown).

Discussion
The small number of commercial antifungal agents, the inappropriate pharmacokinetics and the toxic effects are important factors related to unsuccessful treatments of cryptococcosis and other mycosis. Consequently there is an increasing need for new compounds with antifungal activity. Natural products, including plants, may be a source of compounds with antifungal effects and therefore possible candidates for the development of new antifungal agents [21,22].

In this study, we observed the activity of subfraction F2.4 (a hexameric compound) extracted from the stem bark of barbatimão, against three strains of C. neoformans with different capsule expressions. The acapsular mutant Cap 67 was more susceptible than the capsular strains; although only small differences were observed between MIC values of the three strains the MFC results for the capsular strains was at least 8 times higher than for the acapsular one. These data suggest that the presence of a capsule surrounding C. neoformans cells may influence the antifungal activity of the hexameric compound (Table 1). Interestingly, the presence of a capsule did not interfere with the action of fluconazole, itraconazole or amphotericin B.

Yeasts treated with sub-inhibitory concentrations of subfraction F2.4 showed changes in cell morphology and also their cell size and capsule size decreased significantly when compared to untreated yeasts. The treatment with hexameric compound may interfere with the uptake of nutrients important for normal fungal development.

Several ultrastructural alterations of C. neoformans treated with subfraction F2.4 were observed including the presence of yeasts with altered shape, an amorphous material shading from the cell wall, an increase in the size of vacuoles, appearance of membranous structures and mitochondria swelling. Similar mitochondrial alterations were previously reported by Holetz et al. after treatment of protozoan by tannins [9]. These authors suggested the involvement of the tannins in the oxidative phosphorylation and electron transport defects. Interestingly, yeasts of the acapsular mutant C. neoformans Cap 67 showed more drastic ultrastructural alterations than the other strains.

The formation and budding of vesicles in the vacuoles lumen can be characterized as autophagic bodies, suggesting death of C. neoformans by autophagy [23]. In addition, the structures of concentric membranes are similar to myelin-like figures, which are also related to an autophagic process [24]. These structures were more frequently observed in the treated Cap 67 strain. Although autophagy is a cell mechanism that is necessary for the survival and pathogenesis of many fungi, including C. neoformans [25,26], it is also a mechanism of fungal death induced by antifungal drugs [27-29].

In a previous study, we demonstrated antifungal activity of subfraction F2.4 extracted from barbatimão against C. albicans isolates [13]. We observed growth inhibition and alteration of the cell wall of C. albicans, which may be related to a change in cell surface hydrophobicity, decrease in the capacity of adherence to eukaryotic cells and glass surfaces, inhibition of germ-tube formation and stimulus of phagocytosis by macrophages. The anti-candidal activity was related to the polymeric tannin present in subfraction F2.4 (hexameric compound), which is composed of monomeric units of proanthocyanidins (prodelphinidins and prorobinetinidins) and gallic-acid residues.

A wide range of antimicrobial activity (against filamentous fungi, yeasts and bacteria), stimulation of phagocyte...
cells and host-mediated tumour activity have been assigned to tannins [30]. Polyphenols may precipitate and/or complex with a variety of macromolecules, including polysaccharides, proteins, alkaloids, polymers and cyclodextrins [31]. They appear to associate with macromolecules through non-specific forces such as hydrogen bonding to H-bond-accepting groups and hydrophobic interactions arising from the aromatic rings in their gallic acids, as well as by covalent-bond formation [31]. The increase in tannin polymerisation also increases the degree of intermolecular reaction [32]. In addition, the number of hydroxyl groups on the B-ring affects the level of growth inhibition of many microorganisms [33], suggesting that the trihydroxylated B-rings of proanthocyanidins may have higher antimicrobial action [13]. Thus, the antifungal activity of subfraction F2.4 polymeric tannin against C. neoformans strains may be related to the ability of tannins to inhibit extracellular microbial enzymes, deprivation of substrates and metal-ion cell-envelope transport proteins and the direct action on microbial metabolism through inhibition of oxidative phosphorylation [33].

The capsular compounds GXM and GalXM are synthesized intracellularly, transported to the extracellular space inside membrane vesicles and then released extracellularly for capsular enlargement. However, it is not clear how GXM and GalXM fibres are incorporated into the capsule [34]. It has been suggested that capsular assembly in C. neoformans results from divalent cation-mediated self-aggregation of extracellular-accumulated GXM molecules [35]. Interestingly, the hexameric compound of subfraction F2.4 promoted a reduction of the capsule size and this effect seemed to be dose-dependent. He et al. [36] showed that hydrogen bonding is the predominant effect in the interactions between galactomannins and carbohydrates. Subfraction F2.4 polymeric tannin could act by inhibiting the incorporation of capsular components by hydrogen bonding or divalent-cation scavenging. However, we observed that anti-cryptococcal activity of subfraction F2.4 previously incubated with the supernatant of C. neoformans T1-444 strain culture (rich in capsular components) was similar to that of subfraction F2.4 alone (data not shown). Together, these data suggest that the hexameric compound of subfraction F2.4 is not inhibiting the incorporation of capsular components but is probably interfering in other processes, such as the synthesis of capsular compounds and/or the transport of vesicles to the extracellular moiety.

Melanin is a pigment produced by several pathogenic fungi and is considered to be an important virulence factor for C. neoformans [18]. Its synthesis depends on laccase and also on the presence of exogenous substrates (such as L-dopa and epinephrine). Laccase is a phenoloxidase enzyme present in the cell wall that possesses a broad spectrum of activity, oxidizing polyphenolic compounds. Although the details of the chemical structure of melanin are largely unknown, it is believed to be a cross-linked polymer of phenol and indole subunits that are organized in many spherical granular particles arranged in multiple concentric layers in the cell wall [37]. Recently, Rodrigues et al. [38] demonstrated the secretion of pathogenesis-related molecules, including a laccase, by transf-cell-wall transport into membrane vesicles.

Baurin et al. [39] showed that the extract from stem bark of barbatimão strongly inhibits (close to 90%) Neurospora crassa tyrosinase, a phenoloxidase enzyme. We suggest that the hexameric compound of subfraction F2.4 could inhibit the synthesis of melanin by inhibiting laccase enzyme or by inhibiting cross linking of phenol and indole units. Analyzing the protein alignment of human tyrosinase (E.C.1.14.18.1) and C. neoformans laccase (E.C.10.32), both phenoloxidase enzymes, we can observe low similarity comparing both aminoacid sequences, using the NCBI BLAST databases at National Center for Biotechnology Information (NCBI - [http://www.ncbi.nlm.nih.gov]) (data not show). These data may explain the possible selectivity of the hexameric compound for C. neoformans laccase enzyme. In addition, interference in the nutrient acquisition and changes in the cell wall morphology caused by the treatment with hexameric compound of subfraction F2.4 could also be interfering with the melanin synthesis and its destination. Disturbance of the homeostasis of melanin synthesis by the hexameric compound of subfraction F2.4 could decrease the virulence and pathogenesis of C. neoformans. Interestingly, the presence of a capsule in C. neoformans interferes with the inhibition of pigmentation by subfraction F2.4. Furthermore, we did not observe interference in melanin synthesis of B19F19 cells in concentrations ≤100 µg/ml, which may imply a selective action of the polymeric tannin from barbatimão on C. neoformans.

The cytotoxic effect of the subfraction F2.4 from S. adstringens was previously evaluated against mammalian cells (Vero, macrophage J774G8 and red blood cells) by Ishida et al [13]. The cytotoxic concentration of 50% (CC50) of the subfraction F2.4 for those cells was higher than 100 µg/ml [13]. It represented a selective index (SI = CC50/MIC) to C. neoformans of 33 and 20 to Vero and J774G8 cells, respectively. In addition, no haemolytic effect was observed in concentrations lower than 1000 µg/ml of the subfraction F2.4 [13]. In contrast, polyene agents (such as amphotericin B) show a larger haemolytic pattern when compared to the crude extract of S. adstringens [11].

**Conclusion**

In accordance with previous studies reported on C. albicans [13], the hexameric compound extracted from barbatimão works on C. neoformans as a cytostatic antifungal
agent. It displays an important biological activity against
*C. neoformans* interfering with: cellular homeostasis, yeast
growth, polysaccharide capsule formation and fungal pig-
mentation. In addition, the subfraction F2.4 presented
low citotoxicity against mammalian cells [13].

These data together show the potential of the hexameric
compound to start the development of a new antifungal
agent to treat not only cryptococcosis or candidiasis but it
could also be used against other types of mycosis.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
KI carried out all experiments and data analysis. KI, SR and CVN participated in the design of the study and in the
manuscript writing. JCPM collaborated in the extraction and identification of the hexameric compound of the sub-
fration F2.4 from *S. adstringens*. All authors have read and
approved the final manuscript.

**Acknowledgements**
This research was supported by grants from the Brazilian agencies: Con-
selho Nacional de Desenvolvimento Científico e Tecnológico (CNPq),
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), PRONEX/Fundação Araucária and Financiadora de Estu-
dos e Projetos (FINEP).

**References**
1. Martins ER, Castro DM, Castellani DC, Dias JD: *Plantas Medicinais*
Imprensa Universitária, UFV, Viçosa, Brazil; 1995.
2. Farmacopéia Brasileira, Parte II, 4o fascículo: *Barbatimão*
Bordodetim cortex. Monografia 176, 4a ed., Atheneu, São Paulo.
2002.
3. Palazzo de Mello JP, Petereit F, Nahrstedt A: Flavan-3-ols and pro-
dolinidins from *Stryphnodendron adstringens*. Phytochemistry 1996,
41:807-13.
4. Palazzo de Mello JP, Petereit F, Nahrstedt A: Proborbinetinidins from
*Stryphnodendron adstringens*. Phytochemistry 1996, 42:857-62.
5. Panizza S, Rocha AB, Gecchi R, Silva RA: *Stryphnodendron barba-
detim (Vellozo) Martius*: teor em tanino na casca e sua
propriedade cicatrizante. Ver Cien Farm 1988, 10:101-6.
6. Bersani-Amado CA, Nakamura CV, Nakamura TU, Martinez M, Mello
JCP: Avaliação das atividades antiinflamatória e antibacteri-
aná do extrato bruto do *Stryphnodendron adstringens* (Barba-
timão) [abstract]. Abstracts of Simpósio de Plantas Medicinais do
Brasil, Universidade Federal de Santa Catarina, Florianópolis; 1996:14.
7. Lima JCS, Doro DTS, De Souza PT: Experimental evaluation of
stem bark of *Stryphnodendron adstringens* (Mart.) Coville
foranti-inflammatory activity. Phytother Res 1998, 12:218-20.
8. Audi EA, Toledo DP, Peres PG, Kimura E, Pereira WKV, Mello JCP,
Nakamura CV, Alves-do-Prado W, Cuman RKN, Bersani-Amado CA:
Gastric antiecrogenic effects of *Stryphnodendron adstringens*
in rats. Phytother Res 1999, 13:264-6.
9. Holetz FB, Ueda-Nakamura T, Dias Filho BP, Mello JCP, Morgado-
Díaz JA, Toledo CEM, Nakamura CV: Biological effects of
extracts obtained from *Stryphnodendron adstringens* on Her-
petomonas samuelpessoa. Mem Inst Oswaldo Cruz 2005,
100:397-401.
10. Herzog-Soares JDA, Alves R, Isac E, Bezerra JC, Gomes MH, Santos
SC, Ferni PH: *Atividade tripanocida in vivo de Stryphnodendron
adstringens* (Barbatimão verdadeiro) e *Caycaropsis brasiliensis*
(pequi). Rev Bras Farmacogn 2002, 12(Suppl 1):1-2.
11. Luize PS, Tiuman TS, Morello LG, Maza PK, Ueda-Nakamura T, Dias-
Filho BP, Cortez DAG, Mello JCP, Nakamura CV: Effects of medic-
inal extracts on growth of *Leishmania (braziliensis)* and *Tryp
-enosoma cruzi*. Braz J Pharm Sci 2003, 41:1-10.
12. Filipé AM, Rincão VP, Benati FJ, Linhares RE, Galina KJ, Toledo CE,
Lopes GC, Mello JC, Nozawa C: Antiviral Effect of *Guazuma
ulmifolia* and *Stryphnodendron adstringens* on Poliovirus and
*Glove Herpevirust*. Bol Fauna Bull 2006, 29:193-5.
13. Ishida K, Mello JC, Cortez DA, Dias Filho BP, Ueda-Nakamura T,
Nakamura CV: *Influence of tannins from Stryphnodendron
adstringens* on growth and virulence factors of *Candida albi-
cans*. J Antimicrob Chemother 2006, 58:942-9.
14. Luize PS, Heitman J: The biology of the Cryptococcusneoformans
species complex. Annu Rev Microbiol 2006, 60:69-105.
15. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly
WG, Sobel JD, Dismukes WE: Practice guidelines for the man-
gement of cryptococcal disease. Clin Infect Dis 2000, 30:710-8.
16. Ashley KE, Tuazon MC, Waterhouse ML, Kazykwy O, Keshaviah PN,
Tansuphasawadikul S, Eamplakopak S, Chaoavahan A, Reller LB,
Jarvis WR, Hall GS, Procop GW: Antifungal susceptibilities of
*Cryptococcus neoformans*. Emerg Infect Dis 2004, 10:143-5.
17. Steenbergen JN, Casadevall A: The origin and maintenance of vir-
ulence for the human pathogenic fungus *Cryptococcus neo-
formans*. Microbes Infect 2003, 5:677-75.
18. Nosanchuk JD, Casadevall A: Impact of melanin on microbial
virulence and clinical resistance to antifungal compounds.
Antimicrob Agents Chemother 2006, 50:3519-28.
19. Frontalini RA, Shadomy HJ, Jacobson ES: Decreased virulence in
stable, acapsular mutants of *Cryptococcus neoformans*. Myco-
pathology 1982, 79:23-9.
20. Clinical and Laboratory Standards Institute: Reference method for
broth dilution antifungal susceptibility testing of yeasts. Approved
standard M27-A2. CLSI, Villanova, PA, USA 2008.
21. Barrett D: From natural products to clinically useful antifun-
gals. Biochim Biophys Acta 2002, 1587:224-33.
22. Abad MA, Ansategui M, Bermejo P: Active antifungal from natural
sources. Arkivoc 2007:116-45.
23. Baba M, Takeshige G, Baba N, Ohsumi Y: Ultrastructural analysis
of the autophagic process in yeast: Detection of autophago-
somes and their characterization. J Cell Biol 1994, 124:903-13.
24. Rodrigues JFC, De Souza W: Ultrastructural alterations in organelles
of *Trichophyton mentagrophytes* induced by different classes of
metabolic inhibitors. Curr Pharm Dis 2008, 9:925-38.
25. Veneaute-Fourrey C, Talbot NJ: Autophagic cell death and its
importance for fungal development biology and pathogene-
sis. Autophagy 2007, 3:126-7.
26. Hu G, Hachim M, Waterhouse ML, Panepinto J, Shin S, Liu X, Gibbons
J, Valyi-Nagy T, Obara K, Jaffe HA, Ohsumi Y, Williamson PR: PI3K
signaling of autophagy is required for starvation tolerance and
virulence of *Candida albicans*. J Clin Invest 2008, 118:186-97.
27. Mapseri P, Dall'Olio G, Calefano A, Vannini GL: Autophage vac-
ular development in *Trichophyton mentogrophytes* exposed in
vitro to miconazole. Med Micol 1984, 22:27-35.
28. Pancaldi S, Dall'Olio G, Poli F, Fasulo MP: Stimulation of the
autophagic activity in blastospores of *Candida albicans*
exposed in vitro to flucosaconazole. Mycoses 1994, 38:55-61.
29. Phillips AJ, Sudbery I, Ramsdale M: Apoptosis induced by enviro-
mental stress and amphotericin B in *Candida albicans*. Proc
Natl Acad Sci USA 2003, 100:14327-32.
30. Cowan MM: Plant products antifungal agents. Clin Microbiol
Rev 1999, 12:564-82.
31. Haslam E: Natural polyphenols (vegetable tannins) as drugs:
Possible modes of action. J Nat Prod 1996, 59:205-15.
32. Field JA, Lettinga G: Toxicity of tannic compounds to microor-
ganisms. In Plant polyphenols Edited by: Henningway RW, Laks PE.
New York: Plenum Press; 1992.673-89.
33. Scalbert A: Antimicrobial properties of tannins. Phytochemistry
1991, 30:3875-83.
34. Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K,
Zaragoza O, Alvarez M, Nakouzi A, Feldmesser M, Casadevall A:
Vesicular polysaccharide export in *Cryptococcus neoformans*
is a eukaryotic solution to the problem of fungal tran-cell
wall transport. Eukaryot Cell 2007, 6:48-59.
35. Nimrichter L, Frases S, Cinelli LP, Visan NB, Nakouzi A, Travassos LR,
Casadevall A, Rodrigues ML: Self-aggregation of *Cryptococcus*

---

**Annals of Clinical Microbiology and Antimicrobials 2009, 8:29**

---

For citation purposes, this is not the final PDF version.
neuroformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell 2007, 6:1400-10.
36. He Q, Shi B, Yao K. Interactions of gallotannins with proteins, amino acids, phospholipids and sugars. Food Chem 2006, 95:250-4.
37. Eisenman HC, Nosanchuk JD, Webber JB, Emerson RJ, Camesano TA, Casadevall A. Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry 2005, 44:3683-93.
38. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC, Casadevall A. Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell 2008, 7:58-67.
39. Baurin N, Arnoult E, Scior T, Do QT, Bernard P. Preliminary screening of some tropical plants for anti-tyrosinase activity. J Ethnopharmacol 2002, 82:155-8.